Last 12 months
Inside the activity.
6 purchase rows · 11 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 3 |
| Dec 2025 | 3 | 0 |
| Jan 2026 | 0 | 4 |
| Feb 2026 | 0 | 4 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 3 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 17, 2021 Filed Jun 21, 2021 20:23 UTC |
THOMSON DAVID S.Chief Operating Officer
|
Exercise / conversionCommon Stock | 10,000 | $1.18 | $11,800.00 |
DisclosureSEC source: 0001209191-21-041996 · doc4.xml · nonDerivative · entry 1 THOMSON DAVID S. · CIK 0001770315 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,513 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 15, 2021 Filed Jun 16, 2021 20:06 UTC |
THOMSON DAVID S.Chief Operating Officer
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 2,858 | $0.00 Strike: $1.18 | $0.00 |
DisclosureSEC source: 0001209191-21-040888 · doc4.xml · derivative · entry 3 THOMSON DAVID S. · CIK 0001770315 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,255 Underlying: Common Stock · 2,858 shares Expires 2027-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| June 15, 2021 Filed Jun 16, 2021 20:06 UTC |
THOMSON DAVID S.Chief Operating Officer
|
SaleCommon Stock | 2,858 | $11.20 | $32,009.60 |
DisclosureSEC source: 0001209191-21-040888 · doc4.xml · nonDerivative · entry 2 THOMSON DAVID S. · CIK 0001770315 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,513 Read SEC document |
| June 15, 2021 Filed Jun 16, 2021 20:06 UTC |
THOMSON DAVID S.Chief Operating Officer
|
Exercise / conversionCommon Stock | 2,858 | $1.18 | $3,372.44 |
DisclosureSEC source: 0001209191-21-040888 · doc4.xml · nonDerivative · entry 1 THOMSON DAVID S. · CIK 0001770315 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,371 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 20:19 UTC |
THOMSON DAVID S.Chief Operating Officer
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $1.18 | $0.00 |
DisclosureSEC source: 0001209191-21-040570 · doc4.xml · derivative · entry 3 THOMSON DAVID S. · CIK 0001770315 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,113 Underlying: Common Stock · 30,000 shares Expires 2027-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 20:19 UTC |
THOMSON DAVID S.Chief Operating Officer
|
SaleCommon Stock | 30,000 | $11.52 | $345,600.00 |
DisclosureSEC source: 0001209191-21-040570 · doc4.xml · nonDerivative · entry 2 THOMSON DAVID S. · CIK 0001770315 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,513 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.50 to $11.68. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 20:19 UTC |
THOMSON DAVID S.Chief Operating Officer
|
Exercise / conversionCommon Stock | 30,000 | $1.18 | $35,400.00 |
DisclosureSEC source: 0001209191-21-040570 · doc4.xml · nonDerivative · entry 1 THOMSON DAVID S. · CIK 0001770315 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,513 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 2,270 additional shares acquired under the Company's 2019 Employee Stock Purchase Plan since the Reporting Person's ownership report filed on January 25, 2021. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 18:33 UTC |
Scimeca DarioGeneral Counsel and Secretary
|
GrantRestricted Stock Units · Derivative | 27,136 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-039273 · doc4.xml · derivative · entry 4 Scimeca Dario · CIK 0001779581 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,136 Underlying: Common Stock · 27,136 shares Expires not disclosed F2 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which each represent a contingent right to receive one share of the Company's Common Stock. F5 · derivative.exercise_date: The RSUs shall vest in three substantially equal annual installments on the anniversary of the grant date of such RSUs, subject to the Reporting Person's continued service to the Company through the applicable vesting dates. F5 · derivative.expiration_date: The RSUs shall vest in three substantially equal annual installments on the anniversary of the grant date of such RSUs, subject to the Reporting Person's continued service to the Company through the applicable vesting dates. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 18:33 UTC |
Scimeca DarioGeneral Counsel and Secretary
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 46,629 | $0.00 Strike: $11.34 | $0.00 |
DisclosureSEC source: 0001209191-21-039273 · doc4.xml · derivative · entry 3 Scimeca Dario · CIK 0001779581 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,629 Underlying: Common Stock · 46,629 shares Expires 2031-06-06 F4 · derivative.exercise_date: The option vests as to 25% of the underlying shares on June 7, 2022 and thereafter in twelve equal installments at the end of each three-month period over the 36 months following such date. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 18:33 UTC |
Scimeca DarioGeneral Counsel and Secretary
|
GrantRestricted Stock Units · Derivative | 45,454 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-039273 · doc4.xml · derivative · entry 2 Scimeca Dario · CIK 0001779581 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,454 Underlying: Common Stock · 45,454 shares Expires not disclosed F2 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which each represent a contingent right to receive one share of the Company's Common Stock. F3 · derivative.exercise_date: The RSUs shall vest in two substantially equal annual installments on the anniversary of the grant date of such RSUs, subject to the Reporting Person's continued service to the Company through the applicable vesting dates. Any unvested RSUs shall vest upon The Reporting Person's termination without cause or resignation for good reason prior to June 7, 2022. F3 · derivative.expiration_date: The RSUs shall vest in two substantially equal annual installments on the anniversary of the grant date of such RSUs, subject to the Reporting Person's continued service to the Company through the applicable vesting dates. Any unvested RSUs shall vest upon The Reporting Person's termination without cause or resignation for good reason prior to June 7, 2022. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 18:33 UTC |
Scimeca DarioGeneral Counsel and Secretary
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 78,106 | $0.00 Strike: $11.34 | $0.00 |
DisclosureSEC source: 0001209191-21-039273 · doc4.xml · derivative · entry 1 Scimeca Dario · CIK 0001779581 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,106 Underlying: Common Stock · 78,106 shares Expires 2031-06-06 F1 · derivative.exercise_date: The option vests as to 25% of the underlying shares on June 7, 2022 and thereafter in twelve equal installments at the end of each three-month period over the 36 months following such date. Any unvested options shall vest and become exercisable upon the Reporting Person's termination without cause or resignation due to good reason prior to June 7, 2022. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 23:47 UTC |
List AlanChief Medical Officer
|
GrantRestricted Stock Units · Derivative | 78,090 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-039300 · doc4.xml · derivative · entry 2 List Alan · CIK 0001858530 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,090 Underlying: Common Stock · 78,090 shares Expires not disclosed F2 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which each represent a contingent right to receive one share of the Company's Common Stock. F3 · derivative.exercise_date: The RSUs shall vest in three substantially equal annual installments beginning on April 26, 2022, subject to the Reporting Person's continued service to the Company through the applicable vesting dates. F3 · derivative.expiration_date: The RSUs shall vest in three substantially equal annual installments beginning on April 26, 2022, subject to the Reporting Person's continued service to the Company through the applicable vesting dates. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 23:47 UTC |
List AlanChief Medical Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 134,186 | $0.00 Strike: $11.34 | $0.00 |
DisclosureSEC source: 0001209191-21-039300 · doc4.xml · derivative · entry 1 List Alan · CIK 0001858530 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,186 Underlying: Common Stock · 134,186 shares Expires 2031-06-06 F1 · derivative.exercise_date: The option vests as to 25% of the underlying shares on April 26, 2022 and thereafter in twelve equal installments at the end of each three-month period over the 36 months following such date. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 22:39 UTC |
KHAZI FAYAZCEO of Elo Life Systems
|
GrantRestricted Stock Units · Derivative | 23,999 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-039281 · doc4.xml · derivative · entry 2 KHAZI FAYAZ · CIK 0001770314 · CEO of Elo Life Systems 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,999 Underlying: Common Stock · 23,999 shares Expires not disclosed F2 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which each represent a contingent right to receive one share of the Company's Common Stock. F3 · derivative.exercise_date: The RSUs shall vest in three substantially equal annual installments on the anniversary of the grant date of such RSUs, subject to the Reporting Person's continued service to the Company through the applicable vesting dates. F3 · derivative.expiration_date: The RSUs shall vest in three substantially equal annual installments on the anniversary of the grant date of such RSUs, subject to the Reporting Person's continued service to the Company through the applicable vesting dates. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 22:39 UTC |
KHAZI FAYAZCEO of Elo Life Systems
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 41,240 | $0.00 Strike: $11.34 | $0.00 |
DisclosureSEC source: 0001209191-21-039281 · doc4.xml · derivative · entry 1 KHAZI FAYAZ · CIK 0001770314 · CEO of Elo Life Systems 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,240 Underlying: Common Stock · 41,240 shares Expires 2031-06-06 F1 · derivative.exercise_date: The option vests as to 25% of the underlying shares on June 7, 2022 and thereafter in twelve equal installments at the end of each three-month period over the 36 months following such date. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 22:37 UTC |
KANE MATTHEW R.Director · President and CEO
|
GrantRestricted Stock Units · Derivative | 763 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-039278 · doc4.xml · derivative · entry 2 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 763 Underlying: Common Stock · 763 shares Expires not disclosed F3 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which each represent a contingent right to receive one share of the Company's Common Stock. F4 · derivative.exercise_date: The RSUs shall vest in three substantially equal annual installments on the anniversary of the grant date of such RSUs, subject to the Reporting Person's continued service to the Company through the applicable vesting dates. F4 · derivative.expiration_date: The RSUs shall vest in three substantially equal annual installments on the anniversary of the grant date of such RSUs, subject to the Reporting Person's continued service to the Company through the applicable vesting dates. F2 · ownership.nature: Employee Stock Option is held by Chelsea Lynam Kane, the spouse of the reporting person. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 22:37 UTC |
KANE MATTHEW R.Director · President and CEO
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 1,312 | $0.00 Strike: $11.34 | $0.00 |
DisclosureSEC source: 0001209191-21-039278 · doc4.xml · derivative · entry 1 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 1,312 Underlying: Common Stock · 1,312 shares Expires 2031-06-06 F1 · derivative.exercise_date: The option vests as to 25% of the underlying shares on June 7, 2022 and thereafter in twelve equal installments at the end of each three-month period over the 36 months following such date. F2 · ownership.nature: Employee Stock Option is held by Chelsea Lynam Kane, the spouse of the reporting person. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 22:35 UTC |
Barton ShaneVP & Corporate Controller
|
GrantRestricted Stock Units · Derivative | 18,181 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-039276 · doc4.xml · derivative · entry 2 Barton Shane · CIK 0001836297 · VP & Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,181 Underlying: Common Stock · 18,181 shares Expires not disclosed F2 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which each represent a contingent right to receive one share of the Company's Common Stock. F3 · derivative.exercise_date: The RSUs shall vest in three substantially equal annual installments on the anniversary of the grant date of such RSUs, subject to the Reporting Person's continued service to the Company through the applicable vesting dates. F3 · derivative.expiration_date: The RSUs shall vest in three substantially equal annual installments on the anniversary of the grant date of such RSUs, subject to the Reporting Person's continued service to the Company through the applicable vesting dates. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 22:35 UTC |
Barton ShaneVP & Corporate Controller
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 31,242 | $0.00 Strike: $11.34 | $0.00 |
DisclosureSEC source: 0001209191-21-039276 · doc4.xml · derivative · entry 1 Barton Shane · CIK 0001836297 · VP & Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,242 Underlying: Common Stock · 31,242 shares Expires 2031-06-06 F1 · derivative.exercise_date: The option vests as to 25% of the underlying shares on June 7, 2022 and thereafter in twelve equal installments at the end of each three-month period over the 36 months following such date. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 22:30 UTC |
Kelly John AlexanderChief Financial Officer
|
GrantRestricted Stock Units · Derivative | 40,908 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-039269 · doc4.xml · derivative · entry 4 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,908 Underlying: Common Stock · 40,908 shares Expires not disclosed F2 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which each represent a contingent right to receive one share of the Company's Common Stock. F5 · derivative.exercise_date: The RSUs shall vest in three substantially equal annual installments on the anniversary of the grant date of such RSUs, subject to the Reporting Person's continued service to the Company through the applicable vesting dates. F5 · derivative.expiration_date: The RSUs shall vest in three substantially equal annual installments on the anniversary of the grant date of such RSUs, subject to the Reporting Person's continued service to the Company through the applicable vesting dates. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 22:30 UTC |
Kelly John AlexanderChief Financial Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 70,295 | $0.00 Strike: $11.34 | $0.00 |
DisclosureSEC source: 0001209191-21-039269 · doc4.xml · derivative · entry 3 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,295 Underlying: Common Stock · 70,295 shares Expires 2031-06-06 F4 · derivative.exercise_date: The option vests as to 25% of the underlying shares on June 7, 2022 and thereafter in twelve equal installments at the end of each three-month period over the 36 months following such date. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 22:30 UTC |
Kelly John AlexanderChief Financial Officer
|
GrantRestricted Stock Units · Derivative | 68,181 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-039269 · doc4.xml · derivative · entry 2 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,181 Underlying: Common Stock · 68,181 shares Expires not disclosed F2 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which each represent a contingent right to receive one share of the Company's Common Stock. F3 · derivative.exercise_date: The RSUs shall vest in two substantially equal annual installments on the anniversary of the grant date of such RSUs, subject to the Reporting Person's continued service to the Company through the applicable vesting dates. Any unvested RSUs shall vest upon The Reporting Person's termination without cause or resignation for good reason prior to June 7, 2022. F3 · derivative.expiration_date: The RSUs shall vest in two substantially equal annual installments on the anniversary of the grant date of such RSUs, subject to the Reporting Person's continued service to the Company through the applicable vesting dates. Any unvested RSUs shall vest upon The Reporting Person's termination without cause or resignation for good reason prior to June 7, 2022. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 22:30 UTC |
Kelly John AlexanderChief Financial Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 117,159 | $0.00 Strike: $11.34 | $0.00 |
DisclosureSEC source: 0001209191-21-039269 · doc4.xml · derivative · entry 1 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,159 Underlying: Common Stock · 117,159 shares Expires 2031-06-06 F1 · derivative.exercise_date: The option vests as to 25% of the underlying shares on June 7, 2022 and thereafter in twelve equal installments at the end of each three-month period over the 36 months following such date. Any unvested options shall vest and become exercisable upon the Reporting Person's termination without cause or resignation due to good reason prior to June 7, 2022. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 22:25 UTC |
JANTZ DEREKDirector · Chief Scientific Officer
|
GrantRestricted Stock Units · Derivative | 36,590 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-039263 · doc4.xml · derivative · entry 4 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,590 Underlying: Common Stock · 36,590 shares Expires not disclosed F2 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which each represent a contingent right to receive one share of the Company's Common Stock. F5 · derivative.exercise_date: The RSUs shall vest in three substantially equal annual installments on the anniversary of the grant date of such RSUs, subject to the Reporting Person's continued service to the Company through the applicable vesting dates. F5 · derivative.expiration_date: The RSUs shall vest in three substantially equal annual installments on the anniversary of the grant date of such RSUs, subject to the Reporting Person's continued service to the Company through the applicable vesting dates. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 22:25 UTC |
JANTZ DEREKDirector · Chief Scientific Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 62,875 | $0.00 Strike: $11.34 | $0.00 |
DisclosureSEC source: 0001209191-21-039263 · doc4.xml · derivative · entry 3 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,875 Underlying: Common Stock · 62,875 shares Expires 2031-06-06 F4 · derivative.exercise_date: The option vests as to 25% of the underlying shares on June 7, 2022 and thereafter in twelve equal installments at the end of each three-month period over the 36 months following such date. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 22:25 UTC |
JANTZ DEREKDirector · Chief Scientific Officer
|
GrantRestricted Stock Units · Derivative | 59,090 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-039263 · doc4.xml · derivative · entry 2 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,090 Underlying: Common Stock · 59,090 shares Expires not disclosed F2 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which each represent a contingent right to receive one share of the Company's Common Stock. F3 · derivative.exercise_date: The RSUs shall vest in two equal annual installments on the anniversary of the grant date of such RSUs, subject to the Reporting Person's continued service to the Company through the applicable vesting dates. Any unvested RSUs shall vest upon The Reporting Person's termination without cause or resignation for good reason prior to June 7, 2022. F3 · derivative.expiration_date: The RSUs shall vest in two equal annual installments on the anniversary of the grant date of such RSUs, subject to the Reporting Person's continued service to the Company through the applicable vesting dates. Any unvested RSUs shall vest upon The Reporting Person's termination without cause or resignation for good reason prior to June 7, 2022. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 22:25 UTC |
JANTZ DEREKDirector · Chief Scientific Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 101,537 | $0.00 Strike: $11.34 | $0.00 |
DisclosureSEC source: 0001209191-21-039263 · doc4.xml · derivative · entry 1 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,537 Underlying: Common Stock · 101,537 shares Expires 2031-06-06 F1 · derivative.exercise_date: The option vests as to 25% of the underlying shares on June 7, 2022 and thereafter in twelve equal installments at the end of each three-month period over the 36 months following such date. Any unvested options shall vest and become exercisable upon the Reporting Person's termination without cause or resignation due to good reason prior to June 7, 2022. Read SEC document |
| May 17, 2021 Filed May 19, 2021 12:44 UTC |
JANTZ DEREKDirector · Chief Scientific Officer
|
SaleCommon Stock | 20,000 | $9.38 | $187,600.00 |
DisclosureSEC source: 0001209191-21-033864 · doc4.xml · nonDerivative · entry 1 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,032,279 F1 · kind: The sale was effected to cover the taxes incurred with the Reporting Person's previous option exercise. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.21 to $9.63. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 14, 2021 Filed May 18, 2021 20:25 UTC |
JANTZ DEREKDirector · Chief Scientific Officer
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 21,514 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-21-033487 · doc4.xml · derivative · entry 3 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,514 shares Expires 2021-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| May 14, 2021 Filed May 18, 2021 20:25 UTC |
JANTZ DEREKDirector · Chief Scientific Officer
|
SaleCommon Stock | 9,673 | $9.17 | $88,701.41 |
DisclosureSEC source: 0001209191-21-033487 · doc4.xml · nonDerivative · entry 2 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,052,279 F1 · kind: All sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise, with shares sold to cover the option exercise price and taxes, and the reporting person retaining all remaining shares. Read SEC document |
| May 14, 2021 Filed May 18, 2021 20:25 UTC |
JANTZ DEREKDirector · Chief Scientific Officer
|
Exercise / conversionCommon Stock | 21,514 | $0.04 | $860.56 |
DisclosureSEC source: 0001209191-21-033487 · doc4.xml · nonDerivative · entry 1 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,061,952 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 13, 2021 Filed May 14, 2021 20:50 UTC |
KANE MATTHEW R.Director · President and CEO
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 21,514 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-21-032773 · doc4.xml · derivative · entry 4 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,514 shares Expires 2021-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| May 13, 2021 Filed May 14, 2021 20:50 UTC |
KANE MATTHEW R.Director · President and CEO
|
SaleCommon Stock | 9,675 | $8.96 | $86,688.00 |
DisclosureSEC source: 0001209191-21-032773 · doc4.xml · nonDerivative · entry 2 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,013,597 F1 · kind: All sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise, with shares sold to cover the option exercise price and taxes, and the reporting person retaining all remaining shares. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.96 to $9.00. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 13, 2021 Filed May 14, 2021 20:50 UTC |
KANE MATTHEW R.Director · President and CEO
|
Exercise / conversionCommon Stock | 21,514 | $0.04 | $860.56 |
DisclosureSEC source: 0001209191-21-032773 · doc4.xml · nonDerivative · entry 1 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,023,272 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 13, 2021 Filed May 14, 2021 20:47 UTC |
JANTZ DEREKDirector · Chief Scientific Officer
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 21,514 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-21-032764 · doc4.xml · derivative · entry 6 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,514 Underlying: Common Stock · 21,514 shares Expires 2021-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| May 13, 2021 Filed May 14, 2021 20:47 UTC |
JANTZ DEREKDirector · Chief Scientific Officer
|
SaleCommon Stock | 9,673 | $9.15 | $88,507.95 |
DisclosureSEC source: 0001209191-21-032764 · doc4.xml · nonDerivative · entry 4 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,040,438 F1 · kind: All sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise, with shares sold to cover the option exercise price and taxes, and the reporting person retaining all remaining shares. Read SEC document |
| May 13, 2021 Filed May 14, 2021 20:47 UTC |
JANTZ DEREKDirector · Chief Scientific Officer
|
Exercise / conversionCommon Stock | 21,514 | $0.04 | $860.56 |
DisclosureSEC source: 0001209191-21-032764 · doc4.xml · nonDerivative · entry 3 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,050,111 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 12, 2021 Filed May 14, 2021 20:47 UTC |
JANTZ DEREKDirector · Chief Scientific Officer
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 21,514 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-21-032764 · doc4.xml · derivative · entry 5 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,028 Underlying: Common Stock · 21,514 shares Expires 2021-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| May 12, 2021 Filed May 14, 2021 20:47 UTC |
JANTZ DEREKDirector · Chief Scientific Officer
|
SaleCommon Stock | 9,676 | $8.72 | $84,374.72 |
DisclosureSEC source: 0001209191-21-032764 · doc4.xml · nonDerivative · entry 2 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,028,597 F1 · kind: All sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise, with shares sold to cover the option exercise price and taxes, and the reporting person retaining all remaining shares. Read SEC document |
| May 12, 2021 Filed May 14, 2021 20:47 UTC |
JANTZ DEREKDirector · Chief Scientific Officer
|
Exercise / conversionCommon Stock | 21,514 | $0.04 | $860.56 |
DisclosureSEC source: 0001209191-21-032764 · doc4.xml · nonDerivative · entry 1 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,038,273 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 10, 2021 Filed May 11, 2021 20:27 UTC |
KANE MATTHEW R.Director · President and CEO
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 21,514 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-21-031670 · doc4.xml · derivative · entry 7 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,514 Underlying: Common Stock · 21,514 shares Expires 2021-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| May 10, 2021 Filed May 11, 2021 20:27 UTC |
KANE MATTHEW R.Director · President and CEO
|
SaleCommon Stock | 9,746 | $8.25 | $80,404.50 |
DisclosureSEC source: 0001209191-21-031670 · doc4.xml · nonDerivative · entry 4 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,001,758 F1 · kind: All sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise, with shares sold to cover the option exercise price and taxes, and the reporting person retaining all remaining shares. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.25 to $8.31. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 10, 2021 Filed May 11, 2021 20:27 UTC |
KANE MATTHEW R.Director · President and CEO
|
Exercise / conversionCommon Stock | 21,514 | $0.04 | $860.56 |
DisclosureSEC source: 0001209191-21-031670 · doc4.xml · nonDerivative · entry 3 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,011,504 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 10, 2021 Filed May 12, 2021 20:03 UTC |
Germano Geno JDirector
|
GrantStock Option (Right to Buy) · Derivative | 32,800 | $0.00 Strike: $8.07 | $0.00 |
DisclosureSEC source: 0001209191-21-032013 · doc4.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,800 Underlying: Common Stock · 32,800 shares Expires 2031-05-09 F1 · derivative.exercise_date: The option vests on the earlier of May 10, 2022 or the day immediately prior to the date of the next annual meeting of the Company's stockholders occurring after May 10, 2021, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. Read SEC document |
| May 10, 2021 Filed May 12, 2021 20:09 UTC |
Sharp ShaliniDirector
|
GrantStock Option (Right to Buy) · Derivative | 32,800 | $0.00 Strike: $8.07 | $0.00 |
DisclosureSEC source: 0001209191-21-032025 · doc4.xml · derivative · entry 1 Sharp Shalini · CIK 0001377202 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,800 Underlying: Common Stock · 32,800 shares Expires 2031-05-09 F1 · derivative.exercise_date: The option vests on the earlier of May 10, 2022 or the day immediately prior to the date of the next annual meeting of the Company's stockholders occurring after May 10, 2021, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. Read SEC document |
| May 10, 2021 Filed May 12, 2021 20:07 UTC |
Schinazi Raymond FDirector
|
GrantStock Option (Right to Buy) · Derivative | 32,800 | $0.00 Strike: $8.07 | $0.00 |
DisclosureSEC source: 0001209191-21-032018 · doc4.xml · derivative · entry 1 Schinazi Raymond F · CIK 0001397607 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,800 Underlying: Common Stock · 32,800 shares Expires 2031-05-09 F1 · derivative.exercise_date: The option vests on the earlier of May 10, 2022 or the day immediately prior to the date of the next annual meeting of the Company's stockholders occurring after May 10, 2021, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. Read SEC document |
| May 10, 2021 Filed May 12, 2021 20:01 UTC |
Buehler KevinDirector
|
GrantStock Option (Right to Buy) · Derivative | 32,800 | $0.00 Strike: $8.07 | $0.00 |
DisclosureSEC source: 0001209191-21-032011 · doc4.xml · derivative · entry 1 Buehler Kevin · CIK 0001792722 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,800 Underlying: Common Stock · 32,800 shares Expires 2031-05-09 F1 · derivative.exercise_date: The option vests on the earlier of May 10, 2022 or the day immediately prior to the date of the next annual meeting of the Company's stockholders occurring after May 10, 2021, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. Read SEC document |
| May 07, 2021 Filed May 11, 2021 20:27 UTC |
KANE MATTHEW R.Director · President and CEO
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 21,514 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-21-031670 · doc4.xml · derivative · entry 6 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,028 Underlying: Common Stock · 21,514 shares Expires 2021-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| May 07, 2021 Filed May 11, 2021 20:27 UTC |
KANE MATTHEW R.Director · President and CEO
|
SaleCommon Stock | 9,742 | $8.57 | $83,488.94 |
DisclosureSEC source: 0001209191-21-031670 · doc4.xml · nonDerivative · entry 2 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,989,990 F1 · kind: All sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise, with shares sold to cover the option exercise price and taxes, and the reporting person retaining all remaining shares. Read SEC document |
| May 07, 2021 Filed May 11, 2021 20:27 UTC |
KANE MATTHEW R.Director · President and CEO
|
Exercise / conversionCommon Stock | 21,514 | $0.04 | $860.56 |
DisclosureSEC source: 0001209191-21-031670 · doc4.xml · nonDerivative · entry 1 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,999,732 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.